Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Becker, Matthew C.
Wang, Thomas H.
Lüscher, Thomas F.
Borer, Jeffrey S.
Mascette, Alice M.
Husni, M. Elaine
Graham, David Y.
Yeomans, Neville D.
Lincoff, A. Michael
Nissen, Steven E.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationBecker, Matthew C., Thomas H. Wang, Lisa Wisniewski, Kathy Wolski, Peter Libby, Thomas F. Lüscher, Jeffrey S. Borer, et al. 2009. “Rationale, Design, and Governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen Or Naproxen (PRECISION), a Cardiovascular End Point Trial of Nonsteroidal Antiinflammatory Agents in Patients with Arthritis.” American Heart Journal 157 (4) (April): 606–612. doi:10.1016/j.ahj.2008.12.014.
Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs). However, the relative cardiovascular safety of these therapies remains uncertain.
The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION) trial will evaluate the cardiovascular safety of celecoxib, ibuprofen, and naproxen. Approximately 20,000 patients with symptomatic osteoarthritis or rheumatoid arthritis at high risk for, or with, established cardiovascular disease will be randomized in this double-blind, triple dummy, multinational, multicenter study. The primary end point is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial will continue until 762 primary events occur with at least 18 months follow-up. Noninferiority of any of the regimens will require a 97.5% upper CI of the hazard ratio (HR) ≤1.33 and point estimate ≤1.12 for both intent-to-treat (ITT) and modified ITT populations.
PRECISION, the first study of patients with high cardiovascular risk chronically treated with a cyclooxygenase-2 selective inhibitor or nonselective NSAID, will define the relative cardiovascular safety profile of celecoxib, ibuprofen, and naproxen and provide data to help guide NSAID use for pain management for this population. (Am Heart J 2009;157:606-12.)
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:35140981
- HMS Scholarly Articles